Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lactate controls glomerular endothelial barrier integrity in lupus nephritis
Jiaxin Lei, Xingyu Zhai, Yixin Wang, Ying Li, Lei Li, Mengdi Liu, Jing Guo, Lingyi Li, Zhezhuyun Chen, Qinghua Cao, Zhichun Liu, Ting Liu, Lin Xu, Zhenke Wen
Jiaxin Lei, Xingyu Zhai, Yixin Wang, Ying Li, Lei Li, Mengdi Liu, Jing Guo, Lingyi Li, Zhezhuyun Chen, Qinghua Cao, Zhichun Liu, Ting Liu, Lin Xu, Zhenke Wen
View: Text | PDF
Research Article Nephrology

Lactate controls glomerular endothelial barrier integrity in lupus nephritis

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) is a progressive autoimmune disease that affects multiple organs and tissues, with lupus nephritis (LN) as one of its most severe complications. Although LN progression is associated with compromised permeability of human renal glomerular endothelial cells (HRGECs), the underlying mechanisms are not fully defined. Herein, we demonstrate that aberrant glycolysis drives this glomerular endothelial barrier defect by suppressing the transcription of tight junction (TJ) genes. Mechanistically, circulating self-DNA in SLE plasma acts as a ligand that activates the cGAS/STING pathway in HRGECs, driving aberrant glycolytic adaption. The resulting glycolytic product, lactate, serves as a substrate for protein lactylation, leading to extensive lactylation and subsequent ubiquitination of enhancer of zeste homolog 2 (EZH2). In consequence, EZH2 deficiency results in reduced H3K27me3 levels, thereby suppressing the transcription of TJ genes. In a self-DNA–induced SLE model, inhibition of cGAS/STING signaling or lactate production effectively restored the integrity of TJs of HRGECs and concurrently alleviated key LN symptoms. Together, lactate programs lactylation and ubiquitination of EZH2 to impair the glomerular endothelial barrier in human SLE.

Authors

Jiaxin Lei, Xingyu Zhai, Yixin Wang, Ying Li, Lei Li, Mengdi Liu, Jing Guo, Lingyi Li, Zhezhuyun Chen, Qinghua Cao, Zhichun Liu, Ting Liu, Lin Xu, Zhenke Wen

×

Figure 7

RU.521 and oxamate exert a therapeutic effect by restoring TJ barrier damage and ameliorating LN-related symptoms.

Options: View larger image (or click on image) Download as PowerPoint
RU.521 and oxamate exert a therapeutic effect by restoring TJ barrier da...
(A) Urinary 4 kDa FITC-dextran fluorescence intensity normalized to creatinine was measured via microplate reader in SLE model mice treated with or without RU.521. Data shown as mean ± SEM (n = 4 per group). (B) Glomerular localization of 70 kDa FITC-conjugated dextran in SLE model mice (with or without RU.521 treatment) was visualized by immunofluorescence microscopy. Scale bar: 50 μm. (C) Urinary 4 kDa FITC-dextran fluorescence intensity normalized to creatinine was measured via microplate reader in SLE model mice treated with or without oxamate. Data shown as mean ± SEM (n = 4 per group). (D) Immunofluorescence microscopy was used to visualize the glomerular localization of 70 kDa FITC-conjugated dextran in SLE model mice (with or without oxamate treatment). Scale bar: 50 μm. (E–I) SLE model mice were treated with or without RU.521. (E) Plasma levels of anti-dsDNA IgG were measured using an ELISA kit. (F) Proteinuria normalized to creatinine was quantified via Bradford protein assay. (G) Albuminuria normalized to creatinine was quantified via BCG albumin assay kit. (H) Glomerular pathological changes were visualized by periodic acid–Schiff (PAS) staining. Scale bar: 20 μm. (I) Glomerular localization of IgG was detected by immunofluorescence. Scale bar: 20 μm. Mean ± SEM from 4 mice per group (E–G). (J–N) SLE model mice were administered with or without oxamate. (J) Plasma concentrations of anti-dsDNA IgG were determined using an ELISA kit. (K) Proteinuria normalized to creatinine was quantified via Bradford protein assay. (L) Albuminuria normalized to creatinine was quantified via BCG albumin assay kit. (M) Pathological alterations in glomeruli were observed via PAS staining. Scale bar: 20 μm. (N) Localization of IgG in glomeruli was visualized through immunofluorescence. Scale bar: 20 μm. Mean ± SEM from 4 mice per group (J–L). **P < 0.01, ***P < 0.001, and ****P < 0.0001 with unpaired 2-tailed t test (A, C, E–G, and J–L).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts